You developed your product or service offering. It solves a real problem for your biopharma customers. You know who your customers are. You trained your sales team and sent them on their way to grow your business.
But something isn’t right.
Traction is not where it should be. Marketing is struggling to fill the funnel. Commercial is having a hard time closing deals.
So what’s wrong?
When firmographic segmentation falls short
Too often, companies segment their customers based solely on firmographic characteristics—labels like radiopharmaceutical developers, small biotech companies, or mid‑sized CDMOs. These descriptors tell you what the company is, but not how it behaves or why it makes decisions.
Firmographics alone can mislead you into thinking you’re targeting the right companies—when in reality, you’re simply casting too wide. It’s a bit like fishing in the open ocean.
You know there are fish out there—maybe even the species you want—but the ocean is vast, unpredictable, and full of things you’re not trying to catch. You burn time, resources, and effort hauling in a huge net… only to sort through piles of fish you don’t need, can’t use, or that will never “bite” on what you’re offering.
It’s volume without precision. Effort without certainty. Activity without guaranteed outcomes.
Why Firmographics Alone Don’t Predict Buying Behavior
Consider two biotech companies that look identical on paper: both are early‑stage startups, both are developing a biologic molecule in the preclinical phase, both are operating in the same therapeutic area, and both are located in the same geographic region.
Company ABC is developing its biologic with the goal of out‑licensing before entering the clinic.
Company DEF is developing its biologic but plans to take it through all clinical phases and commercialize it themselves.
Firmographically, they belong to the same segment. Behaviorally, they couldn’t be more different.
Company ABC is optimizing for speed and minimal capital investment. Its value will come from licensing fees, not long‑term commercialization. It will prioritize solutions that accelerate preclinical milestones and make its asset attractive to a future partner.
Company DEF, on the other hand, is building for the long haul. It cares about scalability, compliance, supply chain robustness, and lifecycle cost. Its decisions reflect a multi‑year horizon.
If your product or service is designed for long‑term operational excellence, DEF will see the value immediately. ABC may not—even though both companies sit in the same firmographic bucket.
This is the core problem: Firmographics describe the company. Outcomes describe the motivation. Behavior describes the decision.
Moving beyond firmographics: What really drives segmentation
What characteristics can make companies in the same firmographic segment behave differently?
Strategic intent (short‑term vs. long‑term)
Funding stage and financial health
Risk tolerance
Adoption mindset (innovators vs. late adopters)
Internal capabilities and infrastructure
Regulatory posture
Leadership philosophy
Speed of decision‑making
These are the factors that help you identify behavioral, psychographic, or outcomes‑based segments—the segments that actually predict buying behavior.
Behavioral or outcomes‑based segmentation: Fishing in the right inlet
If firmographic segmentation is casting a net into the open ocean, then:
Behavioral or outcomes‑based segmentation is like fishing in a well‑understood inlet during peak season.
An inlet is smaller, more contained, and rich with exactly the species you’re targeting. You know their patterns—when they feed, what they respond to, how they behave. You’re not guessing; you’re aligning your approach with the natural behavior of the fish.
You catch more of the right fish with less effort.
You use the right bait because you understand what they’re hungry for.
You’re fishing where the fish already are—not where you hope they might be.
This is what behavioral segmentation enables. Once you identify the segments whose problems your product or service solves best—and where you have the greatest potential to grow—your entire commercial approach becomes sharper.
Your value proposition becomes clearer. Your messaging becomes more relevant. Your sales team becomes more effective.
Think of your product or service as a bridge between where your target customer is today and where they want to be. Segmentation tells you which customers are actually trying to cross that bridge.
Targeting the right stakeholders
In B2C environments, segments and personas are often blurred. In B2B—especially in biopharma—they are very different:
Segments = the types of companies you are targeting
Personas = the individuals within those companies who influence or make decisions
Personas are critical because companies don’t buy—people do.
Who are the individuals representing their organization in the decision process?
What is their role?
Are they decision-makers or influencers?
What motivates them?
How do they learn about new solutions?
Who do they trust?
What do they read, attend, or follow?
When you understand these dynamics, you can tailor your communication strategy so your message lands with the right person, in the right way, at the right time.
This clarity also becomes the foundation for truly targeted campaigns. When you know which segments you’re pursuing and which personas within those segments drive decisions, your outreach becomes far more precise. Instead of broad, generic messaging, you can design campaigns that speak directly to the priorities, language, and pain points of the stakeholders who matter most.
Targeting isn’t about reaching more people—it’s about reaching the right people with relevance, clarity and intent.
Bringing it all together
Segmentation is not a box‑checking exercise. It is the foundation of effective biopharma marketing and commercial strategy.
Firmographics tell you who they are.
Behavior tells you how they make decisions.
Outcomes tell you what they are trying to achieve.
Personas tell you who you must influence.
When you combine these layers, you stop casting a wide net into the open ocean and start fishing in the inlet where the right customers already gather.
That’s when traction improves. Marketing becomes efficient. Commercial teams close deals.
And that’s when your product or service reaches the customers it was truly built to serve.
